If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
DelveInsights, Peripheral Lung Cancer -Pipeline Insights, 2016, report
provides comprehensive insights about pipeline drugs across this indication. A
key objective of the report is to establish the understanding for all the 12
pipeline drugs that fall under the category of Peripheral Lung Cancer.
Peripheral lung cancer usually begins in tissues that lie near the outer parts
of the lungs, and may be diagnosed later in due course of time.
The report also provides the recent trends as these days companies are focusing
on the Targeted Therapy for cancer majorly on the inner working of the lung
cancer cells and process, which will control their growth and spread.
Morphoteks Farletuzumab is the only monoclonal antibody in Phase II competing
against the other small molecules in development along with Solitomab of Amgen
in Phase I.
Recent report of Delveinsight covers drugs that are being developed with novel
approach to target or intervene along the pathways of tumorigenesis. Currently
in pipeline, we can observe close competition between the Phase II drugs of Big
Pharma such as Pfizer and Eisai along with mid tier companies such as Hanmi,
Axelar and Morphotek. Boehringer is leading both in market as well as in
pipeline with Afatinib in Phase III stage of development.
The new report, provides a Peripheral Lung Cancer Landscape across the globe
The report provides drug profiles which includes product description, MOA,
licensors & collaborators, development partner and chemical information
Comparative analysis at various stages covering Filed, Phase III, Phase II,
Phase I, Preclinical and Discovery stages
Coverage of the Peripheral Lung Cancer pipeline on the basis of target, MOA,
route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for
Peripheral Lung Cancer and also provide company profiling
Pipeline products coverage based on various stages of development from NDA
filings to discovery.
Provides pipeline assessment by monotherapy and combination therapy products,
stage of development and molecule type.
Reasons to Buy:
Complete Pipeline intelligence and complete understanding over therapeutics
development for Peripheral Lung Cancer
Identify the relationship between the drugs and use it for target finding,
drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding Peripheral
Lung Cancer pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing
pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope
Provides strategically significant competitor information, analysis, and
insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline
Gaining a Full Picture of the Competitive Landscape for Evidence based
Peripheral Lung Cancer Overview
Peripheral Lung Cancer (Lung adenocarcinoma)
Diagnosis of adenocarcinoma
Treatment of Adenocarcinoma of the lung
Therapeutics under Development by Companies
Last Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I and IND)
Discovery and Pre-clinical Stage Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Companies involved in Therapeutics Development
List of Tables:
Table 1: Number of Products Under Development for Peripheral Lung Cancer, 2016
Table 2: Number of Products under Development by Companies,2016
Table 3: Last Stage Products (Phase III and Filed),2016
Table 4: Mid Stage Products (Phase II), 2016
Table 5: Early Stage Products (Phase I and IND), 2016
Table 6: Discovery and Pre-clinical Stage Products, 2016
Table 7: Assessment by Monotherapy Products, 2016
Table 8: Assessment by Route Of Administration, 2016
Table 9: Assessment by Stage and Route Of Administration, 2016
Table 10: Assessment by Molecule Type, 2016
Table 11: Assessment by Stage and Molecule Type, 2016
Table 12: Dormant Drugs, 2016
Table 13: Companies Involved in Therapeutic Development, 2016
List of Figures:
Figure 1: Number of Products under Development for Peripheral Lung Cancer,
Figure 2: Last Stage Products (Phase III) 2016
Figure 3: Mid Stage Products (Phase II), 2016
Figure 4:Early Stage Products (Phase I and IND), 2016
Figure 5: Discovery and Pre-clinical Stage Products, 2016
Figure 6: Assessment by Monotherapy Products, 2016
Figure 7: Assessment by Route of Administration, 2016
Figure 8: Assessment by Stage and Route of Administration, 2016
Figure 9: Assessment by Molecule Type, 2016
Figure 10: Assessment by Stage and Molecule Type, 2016